Hepatitis B Virus Infection at All Ages and Stages
Telemedicine Consult - Dr. Gish
Schedule Consult with Dr. Gish

Hepatitis B Virus Infection at All Ages and Stages

 

Hepatitis B Virus Infection at All Ages and Stages

HBV/HDV Co-Infection: Combined and Chronic Infection (Dr. Gish, AASLD The Liver Meeting) In this Q&A-format talk, Dr. Gish reviews the current state of hepatitis delta virus (HDV) — the most severe form of viral hepatitis — covering testing barriers, disease prognosis, and treatment. Key points: U.S. viremic HDV prevalence is likely under 50,000 (potentially warranting orphan drug status), universal HDV screening in all HBsAg-positive patients is increasingly recommended globally (though AASLD still favors risk-based testing), and chronic hepatitis delta progresses to cirrhosis/HCC far faster than HBV alone. On treatment, he highlights that bulevirtide (BLV) improves virologic, biochemical, and clinical outcomes — including pre-transplant survival — with earlier treatment in lower fibrosis stages projected to meaningfully reduce decompensation, transplant, and mortality, and surveys the pipeline of emerging HDV therapies (entry inhibitors, ASOs, siRNA, and others) in development.

Download Presentation


Metadata